Evolus
NASDAQ: EOLSNewport Beach, US · Delaware corporation
Find your way into Evolus
168 people in our graph share verified history with the Evolus team — schools, employers, funds. One of them is your warm intro.
Evolus is an aesthetics company that markets Jeuveau, an injectable neurotoxin treatment offered through providers, along with a membership program (Club Evolus) for consumers. It operates in the medical aesthetics and pharmaceutical products space.
Founders & leadership


Reported raises · per SEC filings
Form D private placements$40M disclosed across 1 round · 2020
▶$40MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
- Simone BlankDirector
- David GillDirector
- Peter FarrellDirector
- Rui AvelarExecutive Officer
- Robert HaymanDirector
- Michael JafarExecutive Officer
- Karah ParschauerDirector
- David MoatazediExecutive Officer, Director
- Vikram MalikDirector
- Lauren SilvernailExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 7
by search overlapCompanies competing with Evolus for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Evolus do?
- Evolus is an aesthetics company that markets Jeuveau, an injectable neurotoxin treatment offered through providers, along with a membership program (Club Evolus) for consumers. It operates in the medical aesthetics and pharmaceutical products space.
- How much funding has Evolus raised?
- Evolus has disclosed $40M raised across 1 round.
- Where is Evolus headquartered?
- Evolus is headquartered in Newport Beach, US.






